2022. Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation. Voprosy onkologii. 67, 2 (May 2022), 246–253. DOI:https://doi.org/10.37469/0507-3758-2021-67-2-246-253.